Načítá se...
Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial
BACKGROUND: Patients with relapsed/refractory B-cell lymphomas have limited treatment options. GERSHWIN is an open-label, single-arm, phase Ib study of obinutuzumab monotherapy in Chinese patients with histologically documented CD20(+) relapsed/refractory chronic lymphocytic leukemia (CLL), diffuse...
Uloženo v:
| Vydáno v: | Cancer Commun (Lond) |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5993131/ https://ncbi.nlm.nih.gov/pubmed/29843792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-018-0300-5 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|